Company Filing History:
Years Active: 2016
Title: Soren Moestrup: Innovator in CD163-Binding Conjugates
Introduction
Soren Moestrup is a notable inventor based in Aarhus N, Denmark. He has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents. His work focuses on the interaction between haptoglobin-haemoglobin complexes and CD163 receptors, which has implications for medical therapies.
Latest Patents
Soren Moestrup holds 1 patent related to his innovative work. His patent, titled "CD163-binding conjugates," describes a haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof that is operably linked to a substance capable of binding a CD163 receptor. This invention also includes a CD163 variant, either membrane-bound or soluble, that can bind at least one haptoglobin-haemoglobin complex. The potential therapeutic applications of this invention are significant, as it opens new avenues for treatment.
Career Highlights
Throughout his career, Soren Moestrup has been associated with Affinicon Aps, where he has been instrumental in advancing research and development in his field. His expertise in biochemistry and innovative thinking has positioned him as a key player in the industry.
Collaborations
Soren Moestrup collaborates with Holger J Moller, contributing to the advancement of their shared research interests. Their partnership exemplifies the importance of teamwork in driving innovation and achieving breakthroughs in scientific research.
Conclusion
Soren Moestrup's contributions to the field of biochemistry, particularly through his patent on CD163-binding conjugates, highlight his role as an innovator. His work has the potential to impact therapeutic strategies significantly.